Lipids & metabolic liver disease
Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study
Authors' conclusion
MAFLD and its subtypes of DM-MAFLD and OW-MAFLD were associated with the extent of atherosclerotic plaques and stenosis, and presence of PolyVD. This study implicated that FLD might be a potential target of intervention for reducing the deleterious effects of MAFLD on systemic atherosclerosis.
Study context
- Population
- Community-based adults; mean age 61.2 ± 6.7 years, 46.6% male
- Participants
- 3,047 adults
- Exposure
- MAFLD vs non-MAFLD
- Outcome
- Extent of atherosclerotic plaques and stenosis (number of 8 vascular sites affected) and presence of polyvascular disease (stenosis in ≥2 vascular sites)
Methodological detailscommunity-based
- Community-based
Main finding
As reported in the abstract
Systemic atherosclerosis
Each group vs Non-MAFLDOdds ratio (presence of PolyVD) (95% CI)
MAFLD
1.55(1.24–1.94)
- MAFLD
- cOR (extent of plaques) 2.14 (95% CI 1.85–2.48)
- MAFLD
- cOR (extent of stenosis) 1.47 (95% CI 1.26–1.71)
Observational data: associations, not effects.
Further findings
| Outcome | cOR (extent of plaques) (95% CI) |
|---|---|
| MAFLD subtypes | 1.63 (1.14–2.34) |
- MAFLD subtypes — DM-MAFLD and OW-MAFLD associated with extent of plaques and stenosis and presence of PolyVD
- All P < 0.05
MAFLD subtypes
- Lean-MAFLD associated only with extent of plaques
Fatty liver disease (FLD) and MD interaction
- FLD interacted with MD to increase odds of systemic atherosclerosis
- P for interaction ≤ 0.055
- FLD per se associated with extent of plaques and stenosis in participants with MAFLD
Original publication
Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study. Cardiovasc Diabetol. Published 13 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →